CUMC Home | Columbia University | Jobs at CUMC | Contact CUMC | Find People
     
Columbia University Medical Center logo,Positioning Line Discover. Educate. Care. Lead., image for New York Skyline  
 

The Dean's Lecture Series
Alexander Ming Fisher Lecture

Dean's Distinguished Lecture in the Basic Sciences

The Cartwright Lecture

Dean's Distinguished Lecture in the Clinical Sciences

David Seegal Alpha Omega Alpha Visiting Professorship Lecture

Heidelberger-Kabat Lecture

Dean's Distinguished Lecture in the Humanities

Innovation in Biological and Medical Sciences Distinguished Lecture

Louisa Gross Horwitz Prize Lecture
2011-2012 events
past events

Samuel Rudin Distinguished Visiting Professorship Lecture

Thomas Q. Morris Symposia


Previous lectures:
2003-2004
2005-2006
2006-2007
2007-2008
2008-2009

Lecture Videos

home


      

Louisa Gross Horwitz Prize Lectures

The Louisa Gross Horwitz Prize was established under the will of the late S. Gross Horwitz through a bequest to Columbia University, and is named to honor the donor's mother. Louisa Gross Horwitz was the daughter of Dr. Samuel David Gross (1805-1889), a prominent surgeon of Philadelphia, and author of the outstanding Systems of Surgery, who served as President of the American Medical Association.  Each year, since its inception in 1967, the Louisa Gross Horwitz Prize has been awarded by Columbia University for outstanding basic research in the fields of biology or biochemistry. The purpose of this award is to honor a scientific investigator, or group of investigators, whose contributions to knowledge in either of these fields are deemed worthy of special recognition.

The Louisa Gross Horwitz Prize website

2014 Louisa Gross Horwitz Press Release



Available Videos:
Speaker: Edvard I. Moser, PhD
Lecture Date: January 16, 2014
Lecture Title: “Grid Cells and Neural Maps of Space”
Speaker: May-Britt Moser, PhD
Lecture Date: January 16, 2014
Lecture Title: “Hippocampus, Space, and Memory”

The 2014 Louisa Gross Horwitz Prize Lecture

James P. Allison, PhD

"Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities"

James P. Allison, PhD
Professor and Chair, Department of Immunology
Executive Director, Immunotherapy Platform
Deputy Director, David H. Koch Center for Applied Research for Genitourinary Cancers
Vivian L. Smith Distinguished Chair in Immunology
University of Texas MD Anderson Cancer Center

Thursday, November 13, 2014
3:30 p.m.
Alumni Auditorium, First Floor
650 West 168th Street


James P. Allison, PhD, is the Vivian L. Smith Distinguished Chair of Immunology and professor and chair of the Department of Immunology at the University of Texas MD Anderson Cancer Center, where he also is executive director of the Immunotherapy Platform and deputy director of the David H. Koch Center for Applied Research for Genitourinary Cancers.

Dr. Allison is a native Texan. He earned both his BS in microbiology and his PhD in biological sciences from the University of Texas at Austin. He was a postdoctoral fellow in the Department of Molecular Immunology at the Scripps Clinic and Research Foundation in La Jolla, Calif., before taking positions in the University of Texas System, Stanford University, UC Berkeley, UCSF, Weill Cornell Medical College, and Memorial Sloan-Kettering Cancer Center. He was also a Howard Hughes Medical Institute Investigator. In 2012 he returned to the University of Texas MD Anderson Cancer Center in Houston. He is a member of several scientific and medical societies, including the National Academy of Sciences, the Institute of Medicine, and the American Academy of Microbiology. He also is a Fellow of the American Association for Cancer Research.

Dr. Allison’s pioneering work has transformed the fields of basic and tumor immunology.   Early in his career, he identified and characterized key molecules involved in T cell activation, including the T cell receptor (TCR), the prototypical costimulatory receptor CD28, and coinhibitory receptor CTLA-4, providing evidence that T cell responses are determined by a complex process involving antigen-driven TCR signaling plus integration of costimulatory and coinhibitory signals. His landmark translational studies showing antibody-mediated blockade of CTLA-4 co-inhibitory function could enhance antitumor immunity and result in tumor rejection in mice prompted clinical development of ipilimumab, a CTLA-4-blocking monoclonal antibody. Ipilimumab is the first drug of its kind to show survival benefit in melanoma patients, and the FDA approved it in 2011 as a standard-­‐of-­‐ care therapy for late-stage melanoma patients. Dr. Allison’s concept of antibody-mediated blockade of immunologic checkpoints as cancer therapy has opened a new field of immunotherapy, with second-generation agents, such as anti-PD-antibodies, currently being investigated in pre-clinical and clinical settings as treatments for cancer.  

Dr. Allison’s laboratory continues to study basic mechanisms that regulate T cell responses while interweaving mouse and human studies to improve existing approaches and develop new strategies for manipulating T cell responses to cure cancer.  Moreover, since arriving at MD Anderson in November 2012, Dr. Allison founded and directs the Immunotherapy Platform to cultivate, support, and test new development of immunology-based drugs and combinations. The Immunotherapy Platform seeks to find reliable biomarkers that can be used to predict patients that are suitable for the different immunotherapies available while also establishing close collaborations with industry to find new reagents (e.g. new checkpoint inhibitors) that may be used as monotherapy or in combination to further improve overall survival of cancer patients.  Additional small trials, in the pre­-­­surgical or neoadjuvant setting, include extensive collection and analysis of samples from tumor and local lymphoid tissues  as well as peripheral blood. The overall goal of the Immunotherapy Platform is to dissect the immunologic impact of novel therapies and combinations as well as to examine the tumor itself for alterations that may render the tumor resistant to specific mechanisms of immune attack. 



back to top

PAST LOUISA GROSS HORWITZ PRIZE WINNERS

2013 John Michael O'Keffe, PhD
University College London
Edvard I. Moser II, PhD
Norwegian University of Science and Technology
May-Britt Moser, PhD
Norwegian University of Science and Technology
2012 Joe Lutkenhaus, PhD
University of Kansas Medical School
Richard Losick, PhD
Harvard University
Lucy Shapiro, PhD
Stanford University School of Medicine
2011 Jeffery C. Hall, Ph.D.
Brandeis University
Michael Rosbash, Ph.D.
Brandeis University
Michael W. Young, Ph.D.
The Rockefeller University
2010 Thomas J. Kelly, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
Bruce Stillman, Ph.D.
President, Cold Spring Harbor Laboratory
2009 Victor R. Ambrose, Ph.D.
University of Massachusetts Medical School
Gary Ruvkun, Ph.D. Harvard Medical School
2008 F. Ulrich Hartl, M.D., Max-Planck-Institute of Biochemistry Martinsried, Germany
Arthur Horwich, M.D., Yale University School of Medicine
2007 Joseph G. Gall, Carnegie Institution
Elizabeth H. Blackburn, University of California, San Francisco
Carol W. Greider, The Johns Hopkins University School of Medicine
2006 Roger D. Kornberg, Stanford School of Medicine
2005 Ada Yonath, Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly of the Weizmann Institute of Science
2004 Tony Hunter, Salk Institute for Biological Studies
Anthony Pawson, University of Toronto
2003 Roderick MacKinnon, Rockefeller University
2002 James E. Rothman, Sloan-Kettering Institute
Randy W. Schekman, University of California, Berkeley
2001 Avram Hershko, Technion-Israel Institute of Technology, Israel
Alexander Varshavsky, California Institute of Technology, CA
2000 H. Robert Horvitz, Massachusetts Institute of Technology, Cambridge, MA
Stanley J. Korsmeyer, Harvard Medical School, Boston, MA
1999 Pierre Chambon, Institute Génétique et de Biologie Moleculaire et Cellulaire,
Université L. Pasteur, Illkirch-Strasbourg, France; Collége de France, Paris
Robert Roeder, Rockefeller University, New York, NY
Robert Tijan, Howard Hughes Medical Institute;University of California at Berkeley
1998 Arnold J. Levine, Rockefeller University, New York, NY
Bert Vogelstein, Johns Hopkins University, Baltimore, MD
1997 Stanley B. Prusiner, University of California, San Francisco
1996 Clay M. Armstrong, University of Pennsylvania, Philadelphia, PA
Bertil Hille, University of Washington, Seattle, WA
1995 Leland H. Hartwell, University of Washington, Seattle, WA
1994 Philippa Marrack, University of Colorado Health Sciences Center
John W. Kappler, University of Colorado Health Sciences Center
1993 Nicole Le Douarin, Institut d'Embryologie Cellulaire et Moléculaire, Nogent-sur-Marne, France
Donald Metcalf, The Walter and Eliza Hall Institute of Medicine, Victoria, Australia
1992 Christiane Nüsslein-Volhard, Max-Planck-Institut für Entwicklungbiologie, Tübingen, Germany
Edward B. Lewis, California Institute of Technology, Pasadena, CA
1991 Richard Ernst, Laboratorium für Physikalische Chemie, Zurich, Switzerland
Kurt Wuthrich, Swiss Federal Institute of Technology, Institut für Molekularbiologie und Biophysik, Zurich, Switzerland
1990 Stephen Harrison, Howard Hudges Medical Institute, Harvard University, Cambridge, MA
Michael G. Rossmann, Purdue University, West Lafayette, IN
Don C. Wiley, Howard Hughes Medical Center, Harvard Univ., Cambridge, MA
1989 Alfred G. Gilman, The University of Texas Southwestern Medical Ctr., Dallas, TX
Edwin G. Krebs, Howard Hughes Medical Institute Research Laboratories, University of Washington, Seattle, WA
1988 Thomas R. Cech, University of Colorado, Boulder, CO
Philip A. Sharp, Massachusetts Institute of Technology, Cambridge, MA
1987 Günter Blobel, The Rockefeller University, New York, NY
1986 Erwin Neher, Max-Planck Institute for Biophysical Chemistry, Gottingen, Germany
Bert Sakmann, Max-Planck Institute for Biophysical Chemistry, Gottingen, Germany
1985 Donald D. Brown, Carnegie Institution of Washington, Baltimore, MD
Mark Ptashne, Harvard University, Cambridge, MA
1984 Michael S. Brown, University of Texas Health Sciences Center, Dallas, TX
Joseph Goldstein, The University of Texas Southwestern Medical Center, Dallas, TX
1983 Stanley Cohen, Vanderbilt University School of Medicine, Nashville, TN
Vitkor Hamburger, Washington University, St. Louis, MO
Rita Levi-Montalcini, Instituto di Biologia Cellulare, Rome, Italy
1982 Barbara McClintock, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Susumu Tonegawa, Massachusetts Institute of Technology, Cambridge, MA
1981 Aaron Klug, Medical Research Council, Laboratory of Molecular Biology, Cambridge, England
1980 Cesar Milstein, Medical Research Council, Laboratory of Molecular Biology, Cambridge, England
1979 Walter Gilbert, Harvard University, Cambridge, MA
Frederick Sanger, Medical Research Council of Molecular Biology, Cambridge, England
1978 David Hubel, Harvard University School of Medicine, Boston, MA
Vernon Mountcastle, Johns Hopkins Univ. School of Medicine, Baltimore, MD
Torsten Wiesel, Rockefeller University, New York, NY
1977 Michael Heidelberger, New York University School of Medicine, New York, NY
Elvin A. Kabat, Columbia University, New York, NY
Henry G. Kunkel, Columbia University, New York, NY
1976 Seymour Benzer, California Institute of Technology, Pasadena, CA
Charles Yanofsky, Stanford University, Stanford, CA
1975 K. Sune D. Bergstrom, Nobel Foundation, Stockholm, Sweden
Bengt Samuelsson, Karolinska Institute, Stockholm, Sweden
1974 Boris Ephrussi, Paris, France
1973 Renato Dulbecco, The Salk Institute, San Diego, CA
Harry Eagle, Albert Einstein College of Medicine
Theodore T. Puck, University of Colorado Medical Ctr., Denver, CO
1972 Stephen W. Kuffler
1971 Hugh E. Huxley, Medical Research Council, Laboratory of Molecular Biology,
Cambridge, England
1970 Albert Claude
George E. Palade, Yale University School of Medicine, New Haven, CT
Keith R. Porter, University of Maryland-Baltimore County, Catonsville, MD
1969 Max Delbrück, California Institute of Technology, Pasadena, CA
Salvador E. Luria, Massachusetts Institute of Techn., Cambridge, MA
1968 H. Gobind Khorana, Massachusetts Institute of Technology, Cambridge, MA
Marshall Warren Nirenberg, National Heart, Lung & Blood Institute, Bethesda, MD
1967 Luis F. Leloir, Instituto de Investigaciones Bioquimicas, Buenos Aires, Argentina


back to top

CUMC Home | © Columbia University | Affiliated with New York-Presbyterian Hospital | Comments | Text-Only Version